AU2016349358B2 - Peptides and methods of treating endometriosis using the same - Google Patents

Peptides and methods of treating endometriosis using the same Download PDF

Info

Publication number
AU2016349358B2
AU2016349358B2 AU2016349358A AU2016349358A AU2016349358B2 AU 2016349358 B2 AU2016349358 B2 AU 2016349358B2 AU 2016349358 A AU2016349358 A AU 2016349358A AU 2016349358 A AU2016349358 A AU 2016349358A AU 2016349358 B2 AU2016349358 B2 AU 2016349358B2
Authority
AU
Australia
Prior art keywords
pif
seq
sample
peptide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016349358A
Other languages
English (en)
Other versions
AU2016349358A1 (en
Inventor
Eytan R. Barnea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioIncept LLC
Original Assignee
BioIncept LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/058877 external-priority patent/WO2016073513A1/en
Application filed by BioIncept LLC filed Critical BioIncept LLC
Publication of AU2016349358A1 publication Critical patent/AU2016349358A1/en
Application granted granted Critical
Publication of AU2016349358B2 publication Critical patent/AU2016349358B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/202IL-3
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/364Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2016349358A 2015-11-03 2016-11-03 Peptides and methods of treating endometriosis using the same Ceased AU2016349358B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPCT/US2015/058877 2015-11-03
PCT/US2015/058877 WO2016073513A1 (en) 2014-11-03 2015-11-03 Pif binding as a marker for immune dysregulation
US201662317628P 2016-04-03 2016-04-03
US62/317,628 2016-04-03
PCT/US2016/060319 WO2017079430A1 (en) 2015-11-03 2016-11-03 Peptides and methods of treating endometriosis using the same

Publications (2)

Publication Number Publication Date
AU2016349358A1 AU2016349358A1 (en) 2018-06-14
AU2016349358B2 true AU2016349358B2 (en) 2019-12-05

Family

ID=58663080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016349358A Ceased AU2016349358B2 (en) 2015-11-03 2016-11-03 Peptides and methods of treating endometriosis using the same

Country Status (5)

Country Link
EP (1) EP3377085A4 (de)
AU (1) AU2016349358B2 (de)
CA (1) CA3004055A1 (de)
IL (1) IL259096A (de)
WO (1) WO2017079430A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017039751A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
EP3341006A4 (de) 2015-08-28 2019-03-13 BioIncept LLC Zusammensetzungen und verfahren zur behandlung von nervenschäden
US20200246424A1 (en) * 2017-07-17 2020-08-06 Bioincept, Llc Peptides and methods of transplantation and restorative organ function
CA3120699A1 (en) * 2018-11-21 2020-05-28 Endomet Biosciences, Inc. Compositions and methods for treating endometriosis
CN113845582B (zh) * 2021-10-15 2022-05-27 南京市妇幼保健院 内源性多肽在制备预防或治疗子宫内膜癌靶向药物中的应用
EP4248985A1 (de) * 2022-03-25 2023-09-27 Consejo Superior de Investigaciones Científicas (CSIC) Peptide für die behandlung von retinitis pigmentosa

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646003A (en) * 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
WO2000063675A1 (en) * 1999-04-16 2000-10-26 Bioincept, Inc. Identification of a serum marker for endometriosis
US20080003178A1 (en) * 2003-10-22 2008-01-03 Barnea Eytan R PIF tetrapeptides
US20150125886A9 (en) * 2003-10-22 2015-05-07 Biolncept, Llc Compositions and methods for modulating the immune system
WO2016073513A1 (en) * 2014-11-03 2016-05-12 Bioincept, Llc Pif binding as a marker for immune dysregulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970496B1 (de) * 2013-03-12 2018-07-18 Institute of Arthritis Research LLC Immunologisch aktives polypeptid
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646003A (en) * 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
WO2000063675A1 (en) * 1999-04-16 2000-10-26 Bioincept, Inc. Identification of a serum marker for endometriosis
US20080003178A1 (en) * 2003-10-22 2008-01-03 Barnea Eytan R PIF tetrapeptides
US20150125886A9 (en) * 2003-10-22 2015-05-07 Biolncept, Llc Compositions and methods for modulating the immune system
WO2016073513A1 (en) * 2014-11-03 2016-05-12 Bioincept, Llc Pif binding as a marker for immune dysregulation

Also Published As

Publication number Publication date
WO2017079430A1 (en) 2017-05-11
EP3377085A1 (de) 2018-09-26
EP3377085A4 (de) 2019-07-17
AU2016349358A1 (en) 2018-06-14
IL259096A (en) 2018-06-28
CA3004055A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
AU2016349358B2 (en) Peptides and methods of treating endometriosis using the same
US20250000942A1 (en) Peptides and methods of transplantation and restorative organ function
US20250152665A1 (en) Mutant Peptides And Methods Of Treating Subjects Using The Same
AU2019202741A1 (en) Compositions and methods for treating acute radiation syndrome
EP1401467B3 (de) Alpha-fetoprotein-peptide und ihre verwendung
US6818741B2 (en) Alpha-fetoprotein peptides and uses therof
US20240358791A1 (en) Peptides and methods of treating dystrophy-related disorders using the same
CA2965973A1 (en) Pif binding as a marker for immune dysregulation
EP1879604B1 (de) Pif-tetrapeptide
US7122522B2 (en) Alpha-fetoprotein peptides and uses thereof
US20250170212A1 (en) Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders
US20110269692A1 (en) Alpha-fetoprotein peptides and uses thereof
EP4066850A2 (de) Peptide und verfahren zur behandlung von dystrophiebedingten erkrankungen damit
US7132400B2 (en) Alpha-fetoprotein peptides and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired